HC Wainwright & Co. analyst Joseph Hafling maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and raises the price target from $60 to $73.
TransCode Therapeutics Reports Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138; Study Demonstrated TTX-MC138 Effective Against Metastatic Pancreatic Cancer On Animal Models
The study involved weekly injection of TTX-MC138 into animals bearing human pancreatic tumors. Treatment was initiated after the tumors were established and continued for 8 weeks. Untreated animals and animals treated
